Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis

Abstract

Horses with hyperkalaemic periodic paralysis were challenged with an oral dose of potassium chloride, and the prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide was evaluated, with at least three weeks separating the trials of each drug. After the administration of potassium chloride without prophylactic medication the horses' clinical signs ranged from generalised fine muscle fasciculations to gross tremors, and weakness with occasional prolapse of the nictitating membrane; plasma potassium concentration increased significantly (P<0–01) from 4·0 ± 0·2 to 6·0 ± 1 ·01 mmol litre 1. After treatment with acetazolamide the administration of potassium chloride resulted in a significant (P<0·02) increase in plasma potassium from 3·7 ± 0·3 to 4·5 ± 0·4 mmol litres and two of five horses showed clinical signs unless the dosage was increased from 2·2 to 4·4 mg kg −1 twice daily. Three of the four horses treated with hydrochlorothiazide showed clinical signs but their plasma potassium did not rise significantly (3·6 ± 0·3 to 4·6 ± 1·0 mmol litres). None of the five horses treated with phenytoin showed clinical signs despite a significant increase in plasma potassium from 3 ·8 ± 0·6 to 5·3 ± 1 ·1 mmol litres (P<0·05). In general the clinical signs were not correlated consistently with the plasma levels of potassium, and phenytoin appeared to prevent the clinical signs in spite of the hyperkalaemia.